We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Teva Pharmaceutical Industries Ltd | NYSE:TEVA | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.02 | 0.14% | 14.00 | 14.13 | 13.81 | 13.92 | 8,987,446 | 01:00:00 |
Data contribute to growing body of evidence supporting the development of deutetrabenazine for the treatment of tardive dyskinesia
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced eight abstracts evaluating deutetrabenazine tablets – formerly referred to as SD-809 – for the treatment of tardive dyskinesia (TD) will be presented at the American Psychiatric Association (APA) 2017 Annual Meeting in San Diego, CA from May 20-24. The data to be presented underscores the company’s efforts to advance research and treatment of patients with TD.
“The data accepted for presentation offers additional analyses from two pivotal Phase III trials, demonstrating the potential of deutetrabenazine in tardive dyskinesia. This type of research is representative of Teva’s commitment to improve our understanding of how to treat this debilitating and undertreated condition,” said Michael Hayden, MD, PhD, President of Global R&D and Chief Scientific Officer at Teva. “The psychiatric community plays a crucial role in identifying and treating tardive dyskinesia, and we are proud to share these data at the prestigious APA Annual Meeting.”
The full set of Teva-sponsored data to be presented includes:
About Deutetrabenazine
Deutetrabenazine, an investigational treatment for tardive dyskinesia, is an oral, inhibitor of vesicular monoamine 2 transporter, or VMAT2, that regulates the levels of neurotransmitters, in the brain. Deutetrabenazine is approved in the United States for the treatment of chorea associated with Huntington’s disease.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has the world-leading innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products. Teva is leveraging its generics and specialty capabilities in order to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion. For more information, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding deutetrabenazine tablets, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
and other factors discussed in our Annual Report on Form 20-F for the year ended December 31, 2016 (“Annual Report”), including in the section captioned “Risk Factors,” and in our other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov and www.tevapharm.com. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170517005532/en/
Teva Pharmaceutical Industries Ltd.IR Contacts:United StatesKevin C. Mannix, 215-591-8912Ran Meir, 215-591-3033orIsraelTomer Amitai, 972 (3) 926-7656orPR Contacts:IsraelIris Beck Codner, 972 (3) 926-7208orUnited StatesDenise Bradley, 215-591-8974Nancy Leone, 215-284-0213
1 Year Teva Pharmaceutical Indu... Chart |
1 Month Teva Pharmaceutical Indu... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions